CXCL16 is a surrogate marker of inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 3, 2008, Pages 283-288

  Lehrke, Michael ^a   Konrad, Astrid ^a   Schachinger, Veronika ^a   Tillack, Cornelia ^a   Seibold, Frank ^b   Stark, Renee ^c   Parhofer, Klaus G ^a   Broedl, Uli C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Crohn's disease; CXCL16; Disease activity; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CXCL16 CHEMOKINE; PATTERN RECOGNITION RECEPTOR; RESISTIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENTERITIS; FEMALE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHEMOKINES, CXC; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, SCAVENGER; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 39049172656     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701679249     Document Type: Article

References (33)

1. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:6-25.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54:1182-93.
4. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 2006;6:9-20.
5. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298-304.
6. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y, et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001;21:1796-800.
7. Shimaoka T, Nakayama T, Kume N, Takahashi S, Yamaguchi J, Minami M, et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003;171:1647-51.
8. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, et al. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166:5145-54.
9. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004;172:6362-72.
10. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004;172:3678-85.
11. Hofnagel O, Luechtenborg B, Plenz G, Robenek H. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb Vasc Biol 2002;22:710-1.
12. Wagsater D, Olofsson PS, Norgren L, Stenberg B, Sirsjo A. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun 2004;325:1187-93.
13. Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U, et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750-5.
14. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007;49:442-9.
15. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004;279:3188-96.
16. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 2006; Oct 19; [Epub ahead of print].
17. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK III, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006;54:765-78.
18. van der Voort R, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB, Figdor CG, et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005;52:1381-91.
19. Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005;3:113.
20. Fukumoto N, Shimaoka T, Fujimura H, Sakoda S, Tanaka M, Kita T, et al. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 2004;173:1620-7.
21. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
22. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
23. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:45.
24. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
25. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
26. Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003;19:358-65.
27. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extra-lymphoid tissue homing potential. J Clin Invest 2001;107:595-601.
28. Yamauchi R, Tanaka M, Kume N, Minami M, Kawamoto T, Togi K, et al. Upregulation of SR-PSOX/CXCL16 and recruitment of CD8+T cells in cardiac valves during inflammatory valvular heart disease. Arterioscler Thromb Vasc Biol 2004;24:282-7.
29. Hase K, Murakami T, Takatsu H, Shimaoka T, Iimura M, Hamura K, et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006;176:43-51.
30. Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, et al. Exclusive increase of CX3CR1(+)CD28(-)CD4(+) T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007;13:837-46.
31. Sans M, Danese S, de la Motte C, de Souza HS, Rivera-Reyes BM, West GA, et al. Enhanced recruitment of CX3CR1+T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 2007;132:139-53.
32. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
33. Fahy OL, Townley SL, McColl SR. CXCL16 regulates cell-mediated immunity to Salmonella enterica serovar Enteritidis via promotion of gamma interferon production. Infect Immun 2006;74:6885-94.